Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D01XUE
|
||||
| Former ID |
DNCL003059
|
||||
| Drug Name |
Tedatioxetine
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Generalized anxiety disorder; Major depressive disorder [ICD9: 300, 300.02, 311, 296.2, 296.3, 710.0; ICD10:F32, F40-F42, F41.1, F33, M32] | Phase 1 | [1] | ||
| Company |
Lundbeck; Takeda Pharmaceuticals
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C18H21NS
|
||||
| Canonical SMILES |
CC1=CC=C(C=C1)SC2=CC=CC=C2C3CCNCC3
|
||||
| InChI |
1S/C18H21NS/c1-14-6-8-16(9-7-14)20-18-5-3-2-4-17(18)15-10-12-19-13-11-15/h2-9,15,19H,10-13H2,1H3
|
||||
| InChIKey |
CVASBKDYSQKLSO-UHFFFAOYSA-N
|
||||
| CAS Number |
CAS 508233-95-2
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| Target and Pathway | |||||
| Target(s) | 5-HT 3 receptor | Target Info | Modulator | [2] | |
| 5-hydroxytryptamine 2C receptor | Target Info | Modulator | [2] | ||
| KEGG Pathway | Calcium signaling pathway | ||||
| Neuroactive ligand-receptor interaction | |||||
| Gap junction | |||||
| Serotonergic synapse | |||||
| Inflammatory mediator regulation of TRP channels | |||||
| PANTHER Pathway | 5HT2 type receptor mediated signaling pathway | ||||
| Reactome | Serotonin receptors | ||||
| G alpha (q) signalling events | |||||
| WikiPathways | Serotonin Receptor 2 and ELK-SRF/GATA4 signaling | ||||
| Monoamine GPCRs | |||||
| GPCRs, Class A Rhodopsin-like | |||||
| Gastrin-CREB signalling pathway via PKC and MAPK | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800023694) | ||||
| REF 2 | Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.